JP4531132B2 - 増殖因子に対する高親和性オリゴヌクレオチドリガンド - Google Patents

増殖因子に対する高親和性オリゴヌクレオチドリガンド Download PDF

Info

Publication number
JP4531132B2
JP4531132B2 JP53664696A JP53664696A JP4531132B2 JP 4531132 B2 JP4531132 B2 JP 4531132B2 JP 53664696 A JP53664696 A JP 53664696A JP 53664696 A JP53664696 A JP 53664696A JP 4531132 B2 JP4531132 B2 JP 4531132B2
Authority
JP
Japan
Prior art keywords
seq
nucleic acid
sequence
pdgf
information
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP53664696A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001500362A5 (https=
JP2001500362A (ja
Inventor
ジェイ． ツースマン，ペネロープ
ラリー ゴールド
ジャンジック，ネボジサ
リングクイスト，スチーブン
パグラティス，ニコス
Original Assignee
ギリード・サイエンシズ・インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/458,423 external-priority patent/US5731144A/en
Priority claimed from US08/458,424 external-priority patent/US5731424A/en
Priority claimed from US08/465,594 external-priority patent/US5846713A/en
Priority claimed from US08/465,591 external-priority patent/US5837834A/en
Priority claimed from US08/479,725 external-priority patent/US5674685A/en
Priority claimed from US08/479,783 external-priority patent/US5668264A/en
Priority claimed from US08/618,693 external-priority patent/US5723594A/en
Application filed by ギリード・サイエンシズ・インコーポレーテッド filed Critical ギリード・サイエンシズ・インコーポレーテッド
Publication of JP2001500362A publication Critical patent/JP2001500362A/ja
Publication of JP2001500362A5 publication Critical patent/JP2001500362A5/ja
Publication of JP4531132B2 publication Critical patent/JP4531132B2/ja
Application granted granted Critical
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/49—Platelet-derived growth factor [PDGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C12N2320/13—Applications; Uses in screening processes in a process of directed evolution, e.g. SELEX, acquiring a new function
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Nanotechnology (AREA)
  • Medical Informatics (AREA)
  • Dermatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP53664696A 1995-06-02 1996-05-30 増殖因子に対する高親和性オリゴヌクレオチドリガンド Expired - Lifetime JP4531132B2 (ja)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US08/458,423 US5731144A (en) 1990-06-11 1995-06-02 High affinity TGFβ nucleic acid ligands
US08/458,424 1995-06-02
US08/458,424 US5731424A (en) 1990-06-11 1995-06-02 High affinity TGFβ nucleic acid ligands and inhibitors
US08/458,423 1995-06-02
US08/465,591 US5837834A (en) 1990-06-11 1995-06-05 High affinity HKGF nucleic acid ligands and inhibitors
US08/465,594 1995-06-05
US08/465,594 US5846713A (en) 1990-06-11 1995-06-05 High affinity HKGF nucleic acid ligands and inhibitors
US08/465,591 1995-06-05
US08/479,783 1995-06-07
US08/479,725 US5674685A (en) 1990-06-11 1995-06-07 High affinity PDGF nucleic acid ligands
US08/479,783 US5668264A (en) 1990-06-11 1995-06-07 High affinity PDGF nucleic acid ligands
US08/479,725 1995-06-07
US08/618,693 US5723594A (en) 1995-06-07 1996-03-20 High affinity PDGF nucleic acid ligands
US08/618,693 1996-03-20
PCT/US1996/008014 WO1996038579A1 (en) 1995-06-02 1996-05-30 High-affinity oligonucleotide ligands to growth factors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2006249182A Division JP2007049997A (ja) 1995-06-02 2006-09-14 増殖因子に対する高親和性オリゴヌクレオチドリガンド

Publications (3)

Publication Number Publication Date
JP2001500362A JP2001500362A (ja) 2001-01-16
JP2001500362A5 JP2001500362A5 (https=) 2004-07-22
JP4531132B2 true JP4531132B2 (ja) 2010-08-25

Family

ID=27569790

Family Applications (2)

Application Number Title Priority Date Filing Date
JP53664696A Expired - Lifetime JP4531132B2 (ja) 1995-06-02 1996-05-30 増殖因子に対する高親和性オリゴヌクレオチドリガンド
JP2006249182A Pending JP2007049997A (ja) 1995-06-02 2006-09-14 増殖因子に対する高親和性オリゴヌクレオチドリガンド

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2006249182A Pending JP2007049997A (ja) 1995-06-02 2006-09-14 増殖因子に対する高親和性オリゴヌクレオチドリガンド

Country Status (9)

Country Link
US (3) US6207816B1 (https=)
EP (2) EP1741780A3 (https=)
JP (2) JP4531132B2 (https=)
AT (1) ATE343638T1 (https=)
AU (1) AU732820B2 (https=)
CA (1) CA2221318C (https=)
DE (1) DE69636656T2 (https=)
ES (1) ES2276405T3 (https=)
WO (1) WO1996038579A1 (https=)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395888B1 (en) * 1996-02-01 2002-05-28 Gilead Sciences, Inc. High affinity nucleic acid ligands of complement system proteins
US6346611B1 (en) * 1990-06-11 2002-02-12 Gilead Sciences, Inc. High affinity TGfβ nucleic acid ligands and inhibitors
US6344321B1 (en) * 1990-06-11 2002-02-05 Gilead Sciences, Inc. Nucleic acid ligands which bind to hepatocyte growth factor/scatter factor (HGF/SF) or its receptor c-met
US6229002B1 (en) 1995-06-07 2001-05-08 Nexstar Pharmaceuticlas, Inc. Platelet derived growth factor (PDGF) nucleic acid ligand complexes
US6242246B1 (en) 1997-12-15 2001-06-05 Somalogic, Inc. Nucleic acid ligand diagnostic Biochip
AU2004242462B2 (en) * 1999-07-29 2008-01-24 Gilead Sciences, Inc. Nucleic acid ligands to hepatocyte growth factor/scatter factor (HGF/SF) or its receptor C-Met and to integrins
DK2070939T3 (da) 2001-05-25 2014-06-23 Univ Duke Modulatorer af farmakologiske midler
EP1501929B1 (de) * 2002-05-06 2013-03-27 Noxxon Pharma AG Cgrp bindende nukleinsäuren
GB0213745D0 (en) 2002-06-14 2002-07-24 Univ Edinburgh Enzyme
US20040022727A1 (en) * 2002-06-18 2004-02-05 Martin Stanton Aptamer-toxin molecules and methods for using same
US20040249130A1 (en) * 2002-06-18 2004-12-09 Martin Stanton Aptamer-toxin molecules and methods for using same
US20050124565A1 (en) * 2002-11-21 2005-06-09 Diener John L. Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
US20040253243A1 (en) * 2003-01-21 2004-12-16 David Epstein Aptamer therapeutics useful in ocular pharmacotherapy
US8853376B2 (en) 2002-11-21 2014-10-07 Archemix Llc Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
US10100316B2 (en) * 2002-11-21 2018-10-16 Archemix Llc Aptamers comprising CPG motifs
US8039443B2 (en) * 2002-11-21 2011-10-18 Archemix Corporation Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
JP2007525177A (ja) 2003-04-21 2007-09-06 アーケミックス コーポレイション 血小板由来増殖因子に対する安定化アプタマーおよび腫瘍治療剤としてのそれらの使用
US20040219663A1 (en) * 2003-04-30 2004-11-04 Page Robert D. Biopolymer array fabrication using different drop deposition heads
US7727969B2 (en) * 2003-06-06 2010-06-01 Massachusetts Institute Of Technology Controlled release nanoparticle having bound oligonucleotide for targeted delivery
NZ592039A (en) * 2003-08-27 2013-03-28 Ophthotech Corp Combination therapy for the treatment of ocular neovascular disorders
HUE038239T2 (hu) 2004-02-12 2018-10-29 Archemix Llc Komplementrendszerrel összefüggõ rendellenességek kezelésében alkalmazható aptamer terapeutikumok
US7803931B2 (en) 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
WO2005086835A2 (en) * 2004-03-05 2005-09-22 Archemix Corp. Aptamers to the human il-12 cytokine family and their use as autoimmune disease therapeutics
US20060193821A1 (en) * 2004-03-05 2006-08-31 Diener John L Aptamers to the human IL-12 cytokine family and their use as autoimmune disease therapeutics
US20080214489A1 (en) * 2004-04-19 2008-09-04 Anthony Dominic Keefe Aptamer-mediated intracellular delivery of oligonucleotides
US7579450B2 (en) * 2004-04-26 2009-08-25 Archemix Corp. Nucleic acid ligands specific to immunoglobulin E and their use as atopic disease therapeutics
EP1789096A4 (en) 2004-09-07 2009-07-08 Archemix Corp APTAMERS FOR THE VON WILLEBRAND FACTOR AND ITS USE AS THERAPEUTICS FOR THROMBOTIC DISEASES
KR20070101226A (ko) * 2004-09-07 2007-10-16 아케믹스 코포레이션 앱타머의 약화학
US7566701B2 (en) * 2004-09-07 2009-07-28 Archemix Corp. Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
EP2436391A3 (en) 2004-11-02 2012-07-04 Archemix LLC Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
CA2601400A1 (en) 2005-03-19 2006-09-28 Medical Research Council Improvements in or relating to treatment and prevention of viral infections
US20090075342A1 (en) * 2005-04-26 2009-03-19 Sharon Cload Metabolic profile directed aptamer medicinal chemistry
US8101385B2 (en) 2005-06-30 2012-01-24 Archemix Corp. Materials and methods for the generation of transcripts comprising modified nucleotides
CA2613442C (en) 2005-06-30 2016-08-23 Archemix Corp. Materials and methods for the generation of fully 2'-modified nucleic acid transcripts
JP2009513135A (ja) 2005-10-28 2009-04-02 プリーシス・ファーマシューティカルズ・インコーポレイテッド エンコードされたライブラリーを用いて興味のある化合物を同定する方法
US7922000B2 (en) * 2006-02-15 2011-04-12 Miraial Co., Ltd. Thin plate container with a stack of removable loading trays
NZ571791A (en) 2006-03-08 2012-03-30 Archemix Llc Complement binding aptamers and anti-C5 agents useful in the treatment of ocular disorders
WO2008150495A2 (en) * 2007-06-01 2008-12-11 Archemix Corp. Vwf aptamer formulations and methods for use
US20080305157A1 (en) * 2007-06-08 2008-12-11 University Of Maryland Office Of Technology Commercialization Encapsulation and separation of charged organic solutes inside catanionic vesicles
US20090233295A1 (en) * 2008-01-29 2009-09-17 Elias Georges Trim59 directed diagnostics for neoplastic disease
US8207298B2 (en) * 2008-05-01 2012-06-26 Archemix Corp. Methods of separating biopolymer conjugated molecules from unconjugated molecules
WO2010099139A2 (en) 2009-02-25 2010-09-02 Osi Pharmaceuticals, Inc. Combination anti-cancer therapy
WO2010099363A1 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099364A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
GB0904957D0 (en) 2009-03-23 2009-05-06 Univ Erasmus Medical Ct Tumour gene profile
GB0915515D0 (en) 2009-09-04 2009-10-07 Ucl Business Plc Treatment of vasculoproliferative conditions
US8841429B2 (en) * 2009-11-03 2014-09-23 Vivonics, Inc. Nucleic acid ligands against infectious prions
US8236570B2 (en) * 2009-11-03 2012-08-07 Infoscitex Methods for identifying nucleic acid ligands
EP3540059A1 (en) 2010-04-16 2019-09-18 Nuevolution A/S Bi-functional complexes and methods for making and using such complexes
GB201013573D0 (en) 2010-08-12 2010-09-29 Ucl Business Plc Treatment
GB201013785D0 (en) 2010-08-17 2010-09-29 Ucl Business Plc Treatment
GB201014026D0 (en) 2010-08-20 2010-10-06 Ucl Business Plc Treatment
WO2012038744A2 (en) 2010-09-22 2012-03-29 Genome Research Limited Detecting mutations
WO2012149014A1 (en) 2011-04-25 2012-11-01 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
GB201120711D0 (en) 2011-12-01 2012-01-11 Univ Erasmus Medical Ct Method for classifying tumour cells
BR112014016939A2 (pt) 2012-01-10 2019-09-24 Noxxon Pharma Ag ácidos nucleicos que se ligam especificamente a cgrp
CA2866696A1 (en) 2012-03-09 2013-09-12 Ucl Business Plc Treatment of cancer
JP6587934B2 (ja) 2012-03-28 2019-10-09 ソマロジック・インコーポレーテッド Ｐｄｇｆおよびｖｅｇｆ結合アプタマー、および、ｐｄｇｆおよびｖｅｇｆが介在する病気の治療へのそれらの使用
GB201205739D0 (en) 2012-03-30 2012-05-16 Ucl Business Plc Treatment of acute inflammation in the respiratory tract
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
DK4374873T3 (da) 2013-07-12 2025-11-03 Astellas Us Llc Middel til brug ved behandling eller forebyggelse af oftalmologiske tilstande
EP3044334B1 (en) 2013-09-09 2020-08-12 Somalogic, Inc. Pdgf and vegf aptamers having improved stability and their use in treating pdgf and vegf mediated diseases and disorders
DE202014010499U1 (de) 2013-12-17 2015-10-20 Kymab Limited Targeting von humaner PCSK9 zur Cholesterinbehandlung
WO2015140722A1 (en) 2014-03-17 2015-09-24 Glaxosmithkline Intellectual Property Development Limited Aptamers for topical delivery
US9605266B2 (en) 2014-07-16 2017-03-28 City Of Hope Cell-specific internalizing RNA aptamers against human CCR5 and uses therefore
WO2016061386A1 (en) * 2014-10-15 2016-04-21 City Of Hope Rna aptamers against transferrin receptor (tfr)
CA3005132A1 (en) 2015-11-18 2017-05-26 Sio2 Medical Products, Inc. Coated syringe for ophthalmic formulations containing a vegf antagonist
CN108290004A (zh) 2015-11-18 2018-07-17 福尔密孔股份公司 含有vegf拮抗剂的预填充塑料注射器
WO2018218013A2 (en) 2017-05-24 2018-11-29 Sio2 Medical Products, Inc. Sterilizable pharmaceutical package for ophthalmic formulations
EP3377100B1 (en) 2015-11-18 2025-02-26 Formycon AG Pre-filled pharmaceutical package comprising a liquid formulation of a vegf-antagonist
US10576128B2 (en) 2016-01-26 2020-03-03 Formycon Ag Liquid formulation of a VEGF antagonist
GB201704953D0 (en) 2017-03-28 2017-05-10 Imp Innovations Ltd Natural killer cells
WO2018215580A1 (en) 2017-05-24 2018-11-29 Formycon Ag Method for sterilizing prefilled plastic syringes containing a vegf antagonist
EP3630043A1 (en) 2017-05-24 2020-04-08 Formycon AG Sterilizable pre-filled pharmaceutical packages comprising a liquid formulation of a vegf-antagonist
WO2019109046A1 (en) 2017-11-30 2019-06-06 Arrakis Therapeutics, Inc. Nucleic acid-binding photoprobes and uses thereof
GB201804514D0 (en) 2018-03-21 2018-05-02 Ucl Business Plc Treatment of pyroptosis
GB201804515D0 (en) 2018-03-21 2018-05-02 Takayuki Takakondo Treatment of necroptosis
GB201804922D0 (en) 2018-03-27 2018-05-09 Ucl Business Plc Traatment
WO2020260277A1 (en) * 2019-06-25 2020-12-30 Albert-Ludwig-Universität Freiburg Method and kit for measuring of analytes in bi-component systems and uses thereof
GB202002711D0 (en) 2020-02-26 2020-04-08 Ucl Business Ltd Treatment
WO2021260193A1 (en) 2020-06-25 2021-12-30 Medimmune Limited Prevention of axonal damage using antibody binding to amyloid beta 1-42
JP2023541632A (ja) 2020-09-15 2023-10-03 インペリアル・カレッジ・イノベーションズ・リミテッド 特発性肺線維症の処置
GB202017673D0 (en) 2020-11-09 2020-12-23 Imperial College Innovations Ltd Treatment of pulmonary arterial hypertensive
EP4475850A1 (en) 2022-02-09 2024-12-18 Imperial College Innovations Limited Treatment of telangiectasia
WO2024047368A1 (en) 2022-09-02 2024-03-07 Imperial College Innovations Limited Natural killer cells
GB202303784D0 (en) 2023-03-15 2023-04-26 Institute Of Cancer Res Royal Cancer Hospital Cancer treatment
WO2024261477A1 (en) 2023-06-20 2024-12-26 Yaqrit Limited Combination of tlr4 antagonist, ornithine and phenylacetate or phenylbutyrate

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE229046T1 (de) 1985-03-30 1987-12-17 Marc Genf/Geneve Ballivet Verfahren zum erhalten von dns, rns, peptiden, polypeptiden oder proteinen durch dns-rekombinant-verfahren.
WO1989006694A1 (en) 1988-01-15 1989-07-27 Trustees Of The University Of Pennsylvania Process for selection of proteinaceous substances which mimic growth-inducing molecules
FI921353A0 (fi) * 1989-09-29 1992-03-27 Jolla Cancer Res Found Inhibering av transformerande vaextfaktor b foer foerhindrande av ackumulation av extracellulaer matris.
US5837834A (en) * 1990-06-11 1998-11-17 Nexstar Pharmaceuticals, Inc. High affinity HKGF nucleic acid ligands and inhibitors
US5674685A (en) * 1990-06-11 1997-10-07 Nexstar Pharmaceuticals, Inc. High affinity PDGF nucleic acid ligands
US5846713A (en) * 1990-06-11 1998-12-08 Nexstar Pharmaceuticals, Inc. High affinity HKGF nucleic acid ligands and inhibitors
US5459015A (en) * 1990-06-11 1995-10-17 Nexstar Pharmaceuticals, Inc. High-affinity RNA ligands of basic fibroblast growth factor
US5668264A (en) * 1990-06-11 1997-09-16 Nexstar Pharmaceuticals, Inc. High affinity PDGF nucleic acid ligands
US5270163A (en) * 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
ZA914750B (en) * 1990-06-20 1992-03-25 Bristol Myers Squibb Co Methods of modulating blood pressure using tgf-beta and antagonists thereof
JPH06508022A (ja) 1991-02-21 1994-09-14 ギリアド　サイエンシズ，インコーポレイテッド 生体分子に特異的なアプタマーおよび生産方法
MX9301135A (es) * 1992-03-06 1993-09-01 Steven G Reed Metodo para tratar infecciones por patogeno de macrofago.
WO1993019783A1 (en) * 1992-04-01 1993-10-14 The Whittier Institute For Diabetes And Endocrinology Methods of inhibiting or enhancing scar formation in the cns
CA2155515A1 (en) * 1993-02-19 1994-09-01 Wendy Waegell Expansion of stem cells in long term bone marrow cultures by neutralization of tgf-.beta.
US6455689B1 (en) * 1993-04-30 2002-09-24 Biognostik Gesellschaft für Biomolekulare Diagnostik mbH Antisense-oligonucleotides for transforming growth factor-β (TGF-β)
JPH09502354A (ja) * 1993-09-08 1997-03-11 ネクスター ファーマスーティカルズ，インコーポレイテッド 核酸リガンドと、同リガンドを製造するための改良された方法
EP1889910A3 (en) * 1993-09-17 2009-09-02 SomaLogic, Inc. Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex

Also Published As

Publication number Publication date
AU5883996A (en) 1996-12-18
AU732820B2 (en) 2001-05-03
EP1741780A3 (en) 2007-03-28
US20060229273A1 (en) 2006-10-12
JP2001500362A (ja) 2001-01-16
ES2276405T3 (es) 2007-06-16
US6207816B1 (en) 2001-03-27
WO1996038579A1 (en) 1996-12-05
CA2221318C (en) 2012-01-24
CA2221318A1 (en) 1996-12-05
DE69636656D1 (de) 2006-12-07
EP0828849A1 (en) 1998-03-18
EP0828849B1 (en) 2006-10-25
DE69636656T2 (de) 2007-10-04
EP0828849A4 (en) 2005-01-19
ATE343638T1 (de) 2006-11-15
JP2007049997A (ja) 2007-03-01
US20030180744A1 (en) 2003-09-25
EP1741780A2 (en) 2007-01-10

Similar Documents

Publication Publication Date Title
JP4531132B2 (ja) 増殖因子に対する高親和性オリゴヌクレオチドリガンド
US5723594A (en) High affinity PDGF nucleic acid ligands
US6346611B1 (en) High affinity TGfβ nucleic acid ligands and inhibitors
US5731144A (en) High affinity TGFβ nucleic acid ligands
US5731424A (en) High affinity TGFβ nucleic acid ligands and inhibitors
US5846713A (en) High affinity HKGF nucleic acid ligands and inhibitors
US6124449A (en) High affinity TGFβ nucleic acid ligands and inhibitors
US5674685A (en) High affinity PDGF nucleic acid ligands
US5668264A (en) High affinity PDGF nucleic acid ligands
JP2003506024A (ja) 肝細胞増殖因子／細胞分散因子（ＨＧＦ）又はその受容体ｃ−ｍｅｔ、及びインテグリン類に対する核酸リガンド
US6762290B1 (en) High affinity vascular endothelial growth factor (VEGF) receptor nucleic acid ligands and inhibitors
US5837834A (en) High affinity HKGF nucleic acid ligands and inhibitors
AU773741B2 (en) High affinity oligonucleotide ligands to growth factors
AU2004206993B2 (en) High affinity oligonucleotide ligands to growth factors
US20060084797A1 (en) High affinity TGFbeta nucleic acid ligands and inhibitors
AU782620B2 (en) High affinity vascular endothelial growth factor (VEGF) receptor nucleic acid ligands and inhibitors
AU2004242532A1 (en) High affinity TGF beta nucleic acid ligands and inhibitors

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20060314

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20060612

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20060731

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060914

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A132

Effective date: 20070130

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20070302

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20070227

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20070416

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070726

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20080812

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100216

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100219

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100316

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100319

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100415

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100609

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130618

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term